MedTrace Logo

National Psoriasis Foundation - Dendritic Cell-Specific Transmembrane Protein (DC-Stamp) Biomarker Study

NCT01123265 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 22

Last updated 2015-09-21

No results posted yet for this study

Summary

The purpose of this study is to determine whether DC-STAMP, a protein on the surface of osteoclast precursors (OCPs), can be used as a biologic marker in Psoriatic Arthritis (PsA). With this marker the investigators hope to learn more about how OCPs develop as well as find out if DC-STAMP predicts PsA severity and how well treatment works in PsA.

Conditions

Interventions

DRUG

Methotrexate

Subjects will start Methotrexate which will be escalated from 7.5 mg weekly to 15 mg/weekly over a 3 week period.

DRUG

Anti-TNF

Anti-TNF to be administered per standard of care within the practice.

Sponsors & Collaborators

  • National Psoriasis Foundation

    collaborator OTHER

  • University of Rochester

    lead OTHER

Principal Investigators

  • Christopher Ritchlin, MD / MPH · University of Rochester

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2014-06-30
Completion
2014-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01123265 on ClinicalTrials.gov